
CRISPR Startup Eyes Looser Rules to Unlock Gene-Editing's Potential
Aurora Therapeutics, a new CRISPR startup backed by Jennifer Doudna, aims to streamline gene-editing drug approvals by developing adaptable treatments that can be personalized without requiring extensive new trials. This approach, targeting conditions like phenylketonuria (PKU), aligns with the FDA's evolving stance on personalized therapies and could revitalize the gene-editing field by making CRISPR-based treatments more accessible.















Discussion
Join the conversation
Be the first to comment